Definitive Contract 75N91023C00043
Award Date
9/18/23
Potential Completion Date
9/17/25
Potential Value
$2M
Federal Agency
National Cancer Institute
Awardee
Malcova Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Newark, CA 94560, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed
Similar Awards
This definitive contract was awarded by the National Institutes of Health National Cancer Institute to Malcova LLC for $452,397. The contract calls for the development of patient-derived anthropomorphic breast phantoms for automated objective assessment of breast x-ray imaging systems. This supports the National Institutes of Health and Centers for Disease Control and Prevention's missions by responding to the 2019 solicitation seeking Small Business Innovation Research proposals related to...
This FY20 Phase I SBIR contract, valued at $454,778, was awarded to Calibermri, Inc. by the National Institutes of Health National Cancer Institute to develop a quantitative biomimetic MRI breast tissue and tumor phantom toward a comprehensive phantom solution for breast cancer diagnostics and treatment monitoring. The contract is a firm fixed price vehicle with a performance period from September 2020 through October 2021 in Boulder, Colorado. The award is responsive to the National...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Phenomapper, LLC, a minority-owned, self-certified small disadvantaged business located in San Jose, California. The $398,952.00 firm-fixed-price contract was awarded on September 16, 2020, with a completion date of September 15, 2021. The contract is for the development of artificial intelligence-aided imaging technology...
This is a $144,220 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Magarray, Inc. for the development of early diagnostic tools using nanotechnology-based imaging and sensing. The contract was awarded on September 28, 2007 and has a completion date of March 27, 2008. Magarray, Inc. is a for-profit manufacturer located in Mountain View, California. The contract is a firm fixed-price definitive contract, which...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institutes of Health (NIH) National Cancer Institute to Radiologics, Inc., a for-profit organization. The contract, valued at $225,000.00, is for the development of FDA-compliant imaging informatics for cancer research under SBIR Topic 365. As a SBIR Phase I award, this contract is set aside for small businesses. The contract has a firm fixed price pricing type and was awarded on September 18, 2017, with...
This $2,399,183 firm-fixed-price SBIR Phase I contract was awarded by the National Cancer Institute (NCI) to Radiologics, Inc., a small business, to conduct research and development on cancer imaging tools and image de-identification software. The contract is part of the NCI's SBIR program, which aims to stimulate technological innovation and increase private sector commercialization of innovations derived from federal R&D. The contract has a period of performance through January 2024 and is...
This is a Phase I Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health, to Akrotome Imaging, Inc. The $249,912 Firm-Fixed-Price contract supports the development of novel imaging agents to expand the clinical toolkit for cancer diagnosis, staging, and surgical guidance. The contract is focused on creating a fluorescence imaging probe that can be topically applied in the surgical cavity following...
<p>This is a $299,813 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Hylapharm LLC, a self-certified small disadvantaged business, under the SBIR Program Phase I. The contract is for the development of "Targeted Nanoparticle Treatment for Breast Cancer Stem Cells." This contract has a Total Small Business set-aside designation. The contract has an ultimate completion date of September 17, 2016.</p>
<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Imaginab, Inc. The contract, valued at $224,264, is for the development of novel imaging agents to expand the clinical toolkit for cancer diagnosis, staging, and treatment. The contract has a firm fixed-price pricing type and a completion date of September 29, 2012.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...